Effects of D3K2 With Periodontal Therapy in Diabetes Mellitus and Stage I-II Periodontitis Patients

Basit Öğe Kaydı
dc.contributor.authorAydogan, Tolga
dc.contributor.authorKarsiyaka Hendek, Meltem
dc.contributor.authorUnsal, Berrin
dc.contributor.authorCifci, Aydin
dc.contributor.authorVarol, Hakan
dc.contributor.authorKisa, Ucler
dc.contributor.authorOlgun, Ebru
dc.date.accessioned2025-01-21T16:38:16Z
dc.date.available2025-01-21T16:38:16Z
dc.date.issued2024
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackground: The aim of this study is to look into the clinical and biochemical outcomes of D3K2 supplementation in addition to nonsurgical periodontal treatment (NSPT) for patients suffering from diabetes mellitus (DM) and periodontitis. Methods: Thirty-eight participants with DM and periodontitis were randomized into two different groups. The test group provided NSPT with D3K2 whereas the control group received NSPT with placebo. Clinical periodontal parameters were recorded and serum and gingival crevicular fluid (GCF) were sampled at baseline and at the third and the sixth months after treatment. Glycated hemoglobin A1c (HbA1c), fasting blood glucose (FBG), 25(OH)D-3, parathyroid hormone (PTH), calcium (Ca) and magnesium (Mg) values were determined in blood samples. GCF and serum interleukin (IL)-1 beta and IL-10 levels were analyzed using enzyme-linked immunosorbent assay. Results: All clinical periodontal parameters were importantly decreased at the third and sixth months after treatment compared to baseline in both groups. At the sixth month, 25(OH)D-3 levels in the test group were observed to be statistically significantly higher than in the control group (p = 0.02). Serum IL-1 beta showed a statistically significant decrease at the sixth month compared to baseline and the third month in control group. Conclusion: According to this study, there is limited additional benefit of D3K2 given with NSPT in individuals with DM and periodontitis.
dc.description.sponsorshipScientific Research Project Fund of Kirikkale University [2022/040]
dc.description.sponsorshipThis research was supported by the Scientific Research Project Fund of Kirikkale University under the project number 2022/040.
dc.identifier.doi10.1111/odi.15147
dc.identifier.issn1354-523X
dc.identifier.issn1601-0825
dc.identifier.pmid39370735
dc.identifier.scopus2-s2.0-85205916115
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1111/odi.15147
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24617
dc.identifier.wosWOS:001329408900001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofOral Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241229
dc.subject25-hydroxyvitamin D3; diabetes mellitus; glycated hemoglobin; periodontitis; vitamin D
dc.titleEffects of D3K2 With Periodontal Therapy in Diabetes Mellitus and Stage I-II Periodontitis Patients
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu